Los Angeles Capital Management LLC Purchases 15,045 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Los Angeles Capital Management LLC grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 152.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 24,929 shares of the company's stock after purchasing an additional 15,045 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.09% of Krystal Biotech worth $4,495,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Commonwealth Equity Services LLC raised its stake in Krystal Biotech by 4.1% in the 4th quarter. Commonwealth Equity Services LLC now owns 4,866 shares of the company's stock valued at $762,000 after acquiring an additional 190 shares during the period. Cibc World Markets Corp bought a new stake in Krystal Biotech in the 4th quarter valued at about $364,000. Xponance Inc. raised its stake in Krystal Biotech by 9.5% in the 4th quarter. Xponance Inc. now owns 1,785 shares of the company's stock valued at $280,000 after acquiring an additional 155 shares during the period. Teacher Retirement System of Texas raised its stake in Krystal Biotech by 27.3% in the 4th quarter. Teacher Retirement System of Texas now owns 6,383 shares of the company's stock valued at $1,000,000 after acquiring an additional 1,369 shares during the period. Finally, Summit Global Investments bought a new stake in Krystal Biotech in the 4th quarter valued at about $541,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of research reports. Guggenheim lowered their price objective on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Bank of America reduced their target price on Krystal Biotech from $193.00 to $192.00 and set a "buy" rating for the company in a report on Tuesday. HC Wainwright reaffirmed a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a report on Tuesday, June 24th. Chardan Capital reaffirmed a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. Finally, Citigroup reaffirmed a "neutral" rating and set a $176.00 target price (up previously from $155.00) on shares of Krystal Biotech in a report on Wednesday, July 9th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $211.33.

Insiders Place Their Bets

In related news, insider Suma Krishnan sold 1,389 shares of the business's stock in a transaction that occurred on Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total value of $208,350.00. Following the completion of the sale, the insider owned 1,508,056 shares in the company, valued at $226,208,400. The trade was a 0.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 49,800 shares of company stock valued at $7,487,943. Insiders own 13.70% of the company's stock.

Krystal Biotech Trading Down 1.1%

Shares of NASDAQ KRYS traded down $1.68 during midday trading on Thursday, hitting $151.57. 76,804 shares of the company's stock were exchanged, compared to its average volume of 316,536. Krystal Biotech, Inc. has a 12-month low of $122.80 and a 12-month high of $219.34. The company has a market cap of $4.38 billion, a price-to-earnings ratio of 36.41 and a beta of 0.67. The business's fifty day moving average price is $137.53 and its two-hundred day moving average price is $155.81.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The business had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. Equities analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).